The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME

International Journal of Oncology

Volumn 39, Issue 5, 2011, Pages 1303-1310

  Vanella, Luca ^a   Di Giacomo, Claudia ^a   Acquaviva, Rosaria ^a   Santangelo, Rosa ^a   Cardile, Venera ^a   Barbagallo, Ignazio ^a   Abraham, Nader G ^b   Sorrenti, Valeria ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Angiogenesis; DDAH; L NAME; NOS; Prostate cancer; VEGF

Indexed keywords

DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HYPOTHESIS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VASCULARIZATION; WESTERN BLOTTING;

AMIDOHYDROLASES; ANGIOGENESIS INHIBITORS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053211511     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1107     Document Type: Article

References (84)

1. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
2. Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P and Tuli S: Predictors of survival in patients with prostate cancer and spinal metastasis. J Neurosurg Spine 13: 789-794, 2010.
3. Nayyar R, Sharma N and Gupta NP: Prognostic factors affecting progression and survival in metastatic prostate cancer. Urol Int 84: 159-163, 2010.
4. Yigitbasi O, Ozturk U, Goktug HN, Gucuk A and Bakirtas H: Prognostic factors in metastatic prostate cancer. Urol Oncol 29: 162-165, 2011.
5. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 46: 467-473, 1986.
6. Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-56, 1989.
7. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1999.
8. Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994. (Pubitemid 24324908)
9. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995.
10. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
11. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Nat Cancer Inst 82: 4-6, 1990.
12. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005. (Pubitemid 43093963)
13. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC and Harris AL: Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvascular density. Chalkeley count, and computer image analysis. J Pathol 177: 275-283, 1995.
14. Weidner N, Carroll P, Flax J, Blumenfeld W and Folkman J: Tumour angiogenesis: correlation with metastases in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993. (Pubitemid 24058195)
15. Brustman H, Riss P and Naude S: The relevance of angiogenesis in benign and malignant epithelial tumours of the ovary: a quantitative histological study. Gynecol Oncol 67: 20-26, 1997. (Pubitemid 27433323)
16. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996. (Pubitemid 26272076)
17. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 23-31, 1995.
18. Moncada S, Palmer RMJ and Higgs EA: Nitric oxide: physiology, pathology and pharmacology. Pharm Rev 43: 109-142, 1991.
19. Xu W, Liu LZ, Loizidou M, Ahmed M and Charles IG: The role of nitric oxide in cancer. Cell Res 2: 311-320, 2002. (Pubitemid 135708343)
20. Chinje EC and Stratford IJ: Role of nitric oxide in growth of solid tumours: a balancing act. Essays Biochem 32: 61-72, 1997. (Pubitemid 127470401)
21. Griffioen AW and Molema G: Angiogenesis: potentials or pharmacologic intervention in the treatment of cancer, cardiovascular disease and crhonic inflammation. Pharm Rev 52: 237-268, 2000. (Pubitemid 30368433)
22. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, Geppetti P and Ledda F: Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance. PJ Clin Invest 94: 2036-2044, 1994. (Pubitemid 24348244)
23. Trachtman H, Futterweit S, Garg P, Reddy K and Singhal PC: Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesengial cells. Biochem Biophys Res Commun 218: 704-708, 1996. (Pubitemid 26050726)
24. Fukumura D, Yuan F, Endo M and Jain RK: Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am J Pathol 150: 713-725, 1997. (Pubitemid 27073798)
25. Chin K, Kurashima Y, Ogura T, Tajiri H, Yoshida S and Esumi H: Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene 15: 437-442, 1997. (Pubitemid 27370993)
26. Papapetropoulos A, Garcia-Cardena G, Madri JA and Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factorin human endothelial cell. J Clin Invest 100: 3131-3139, 1997. (Pubitemid 28022851)
27. Sciarra A, Mariotti G, Salciccia S. Gomez AA, Monti S, Toscano V and Di Silverio F: Prostate growth and inflammation. J Steroid Biochem Mol Biol 108: 254-260, 2008. (Pubitemid 351179630)
28. Aydin A, Arsofa-Sarafinovska Z, Sayal A, Eken A, Erdem O, Erten K, Ozgok Y and Dimovski A: Oxidative stress and antioxidant in non-metastatatic prostate cancer and benign prostatec hyperplasia. Clin Biochem 39: 176-179, 2006. (Pubitemid 43255508)
29. Jung K, Seidel B, Rudolph B, Lein M, Cronauver MV, Henke W, Hampel G, Schnorr D and Loening SA: Antioxidant enzymes in malignant cell lines and in primary cultured prostatic cells. Free Radical Biol Med 23: 127-133, 2007.
30. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V and Moncada S: Nitric oxide synthase activity in human gynecological cancer. Cancer Res 54: 1352- 1354, 1994.
31. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S: Nitric oxide synthase activity in human breast cancer. Br J Cancer 72: 41-44, 1995.
32. Duenas-Gonzalez A, Isales CM, Del Mar Abad-Hernadez M, Gonzalez-Sarmiento R, Sangueza O and Rodriguez-Commes J: Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. Mol Pathol 10: 645-649, 1997. (Pubitemid 27321753)
33. Cobbs CS, Brenman JE, Aldape KD, Bredt DS and Israel MA: Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 55: 727-730, 1995.
34. Thomsen LL and Miles DW: Role of nitric oxide in tumor progression: lessons from human tumors. Cancer Metastasis Rev 17: 107-118, 1998. (Pubitemid 28194649)
35. Klots T, Bloch W, Volberg C, Engelmann U and Addicks K: Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 82: 1897-1903, 1998. (Pubitemid 28208645)
36. Chen GG, Lee TW, Xu H, Yip JH, Li M, Mok TS and Yim AP: Increased inducible nitric oxide synthase in lung carcinoma of smokers. Cancer 112: 372-381, 2008.
37. Lukes P, Pàcovà H, Kucera T, Vesely D, Martinek J and Asti J: Expression of endothelial and inducible nitric oxide synthase and caspase-3 in tonsillar cancer, chronic tonsillitis and healthy tonsils. Folia Biol 54: 141-145, 2008.
38. Brennan PA, Palacios-Callender M, Zaki GA, Spedding AV and Langdon JD: Type II nitric oxide synthase (NOS2) expression correlates with lynphnode status in oral squamous carcinoma. J Oral Pathol Med 30: 129-134, 2001. (Pubitemid 32139982)
39. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA and Ziche M: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90: 587-596, 1998. (Pubitemid 28204802)
40. Jacobi J, Sydow K, Von Degenfeld G, Zhang Y, Dayoub H, Wang B, Patterson AJ, Kimoto M, Blau HM and Cooke JP: Overexpression of dimethyl arginine dimethylamino hydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 22: 1431-1438, 2005. (Pubitemid 40396810)
41. Kostourou V, Robinson SP, Cartwright JE and Whitley GS: Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer 87: 673-680, 2002.
42. Leiper J, Santa Maria J, Chubb A, MacAllister RJ, Charles I, Whithley GSJ and Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology to microbial arginine deiminases, Biochem J 343: 209-214, 1999. (Pubitemid 29473897)
43. Tran CT, Fox MF, Vallance P and Leiper JM: Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 68: 101-105, 2000.
44. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA and Murphy GP: LnCap model of human prostatic carcinoma. Cancer Res 43: 1809-1818, 1983. (Pubitemid 13122588)
45. Hayward SW, Dahiya R, Cunha G R, Bartek J, Deshpande N and Narayan P: Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH1. In Vitro Cell Dev Biol 31A: 14-24, 1995.
46. Pavone A and Cardile V: An in vitro study of new antiepileptic drugs and astrocytes. Epilepsia 44 (Suppl 10): 34-39, 2003. (Pubitemid 37280391)
47. Renis M, Cardile V, Grasso S, Palumbo M and Scifo C: Switching off HSP70 and i-NOS to study their role in normal and H2O2-stressed human fibroblasts. Life Sci 74: 757-769, 2003. (Pubitemid 37494902)
48. Lowry OH, Rosenbrough NJ, Farr AJ and Randall RG: Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275,1951.
49. Knipp M and Vasak M: A colorimetric 96-well microtirer plate assay for the determination of enzymatically formed citrulline. Anal Biochem 286: 257-264, 2000.
50. Liekens S, De Clercq E and Neyts J: Angiogenesis: regulators and clinical application. Biochem Pharmacol 61: 253-270, 2000.
51. Tanigawa N, Amaya H, Matsumura M, Lu C, Kitaoka A and Matsuyama K: Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 57: 1043-1046, 1997. (Pubitemid 27138597)
52. Orucevic A, Bechberger J, Green A M, Shapiro RA, Billiar TR and Lala PK: Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 81: 889-896, 1999. (Pubitemid 29249973)
53. Svec J, Ergang P, Mandys V, Kment M and Pácha J: Expression profiles of proliferative and antiapoptotic genes in sporadic and colitis-related mouse colon cancer models. Int J Exp Pathol 91: 44-53, 2010.
54. Saed GM, Ali-Fehmi R, Jiang ZL, Fletcher NM, Diamond MP, Abu-Soud HM and Munkarah MR: Myeloperoxidase serves as a redox switch that regulates apoptosis in epithelial ovarian cancer. Gynecol Oncol 116: 276-281, 2010.
55. Lecuru F, Metzeger U, Levy E, Lefreree-Belda MA and Bensaid C: Ovarian cancer: diagnosis of early stages, referral of patients and management. Rev Prat 54: 1763-1769, 2004. (Pubitemid 39472097)
56. Wang YZ, Cao YQ, Wu JN, Chen M and Cha XY: Expression of nitric oxide synthase in human gastric carcinoma and its relation to p53, PCNA. World J Gastroenterol 11: 46-50, 2005. (Pubitemid 40090134)
57. Peng JP, Zheng S, Xiao ZX and Zhang SZ: Inducible nitric oxide synthase expression is related to angiogenesis, bcl-2, and cell proliferation in hepatocellular carcinoma. J Zhejiang Univ Sci 4: 221-227, 2003.
58. Narayanan BA, Narayanan NK, Simi B and Reddy BS: Modulation of indicible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res 63: 972-979, 2003. (Pubitemid 36278427)
59. Lim KH, Ancrile BB, Kashatus DF and Counter CM: Tumour maintenance is mediatedby eNOS. Nature 452: 646-649, 2008.
60. Fukumura D, Kashiwagi S and Jain RK: The role of nitric oxide in tumor progression. Nat Rev Cancer 6: 521-534, 2006. (Pubitemid 43980541)
61. Ying L and Hofseth LJ: An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 67: 1407-1410, 2007. (Pubitemid 46383362)
62. Polytarchou C, Hatziapostolou M, Poimenidi E, Papadopoulou A, Parthymou A and Papadimitriou E: Nitric oxide stimulates migration of human endothelial and prostate cancer cells through up-regulation of pleiotrophin expression and its receptor protein tyrosine phosphate beta/zeta. Int J Cancer 124: 1785-1793, 2009.
63. Shang ZJ and Li JR: Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in oral squamous cell carcinoma: its correlation with angiogenesis and disease progression. J Oral Pathol Med 34: 134-139, 2005. (Pubitemid 40293221)
64. Bentz BG, Haines GK, Lingen MW, Pelzer HJ, Hanson DG and Radosevich JA: Nitric oxide synthase type 3 is increased in squamous hyperplasia, dysplasia, and squamous cell carcinoma of the head and neck. Am Otol Rhinol Laryngol 108: 781-787, 1999. (Pubitemid 29372878)
65. Chen G, Qian HS, Liu P, Brooks A, Rubanyi GM and Kauser K: i-NOS derived NO substitutes for endothelial NO in tumor angiogenesis and tumor growth in the absence of ecNOS expression. Nitric Oxide 14: A16, 2006.
66. Hamid ARAH, Umbas R and Mochtar CA: Recent role of inflammation in prostate diseases: chemoprevention development opportunity: Acta Med Indones-Indones. J Intern Med 43: 59-65, 2011.
67. Fujmoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M. Suga, M and Ando M: Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Inst 88: 1190-1198, 1997. (Pubitemid 28048266)
68. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk Huang DJ and Jain RK: Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 98: 2604-2609, 2001. (Pubitemid 32209529)
69. Malone JM, Saed GM, Diamond MP, Sokol RJ and Munkaraha AR: The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer. Am J Obstet Gynecol 194: 1110-1118, 2006.
70. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D'Eletto M, Cianciulli AM, Gallucci M, De Carli P, Sentinelli S, Mottolese M, Carlini P, Strigari L, Finn S, Mueller E, Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S, Sacchi A, Pontecorvi A, Loda M and Farsetti A: Endothelial NOS, estrogen receptor â, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. J Clin Invest 119: 1093-1108, 2009.
71. Tozer GM, Prise VE, Lewis G, Xie S, Wilson I and Hill SA: Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects ocombretastatin a-4 3-o-phosphate at clinically relevant doses. Clin Cancer Res 15: 3781-3790, 2009.
72. Punathil T, Tollefsbol TO and Katiyar SK: EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase. Biochem Biophys Res Commun 375: 162-167, 2008.
73. Yu LB, Dong XS, Sun WZ, Zhao DL and Yang Y: Effect of a nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on invasion of human colorectal cancer cell line SL-174T. World J Gastroenterol 11: 6385-6388, 2005.
74. Kon K, Fujii S, Kosaka H and Fujiwara T: Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester retards vascular sprouting in angiogenesis. Microvasc Res 65: 2-8, 2003. (Pubitemid 36263284)
75. Camp ER, Yang A, Liu W, Fan F, Somcio R, Hicklin DJ and Ellis LM: Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin Cancer Res 12: 2628-2633, 2006.
76. Pullen NA and Fillmore HL: Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide. J Neurooncol 96: 201-209, 2010.
77. Uneda S, Hata H, Matsuno F, Nagasaki A, Harada N, Mitsuya Y, Matsuzaki H and Mitsuya H: A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl- ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br J Haematol 120: 396-404, 2003. (Pubitemid 36241495)
78. Punathil T and Katiyar SK: Inhibition of non-small cell lung cancer cell migration by grape seed proanthocyanidins is mediated through the inhibition of nitric oxide, guanylate cyclase, and ERK1/2. Mol Carcinog 48: 232-242, 2009.
79. Thejass P and Kuttan G: Allyl isothiocyanate (AITC) and phenyl isothiocyanate (PITC) inhibit tumour-specific angiogenesis by downregulating nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha) production. Nitric Oxide 16: 247-257, 2007. (Pubitemid 46149387)
80. Fitzpatrick B, Mehibel M, Cowen RL and Stratford IJ: iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 19: 217-224, 2008.
81. Ohtsu N, Takaoka K, Segawa E, Hashitani S, Noguchi K, Kishimoto H and Urade M: Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2. Oncol Rep 24: 31-36, 2010.
82. Jadeski LC and Lala PK: Nitric oxide synthase inhibition by NG-Nitro-L-Arginine methyl ester inhibits tumor induced angiogenesis in mammary tumors. Am J Pathol 155: 1381-1390, 1999. (Pubitemid 29488945)
83. Davel L, Eijan AM, Sales ME, Espanol A, D'Agostino A, Piccardo I, Lauria L, De Lustig ES and Jasnis MA: Reactivity of tumor-draining lymph nodes and the nitric oxide pathway. Int J Oncol 20: 59-67, 2002.
84. Wang Y, Monzingo AF, Hu S, Schaller TH, Robertus JD and Fast W: Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide. Biochemistry 48: 8624-8635, 2009.